Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27KIP1 as a consequence of c-Abl inhibition
- 1 November 2014
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 92 (2) , 235-250
Abstract
No abstract availableKeywords
Funding Information
- Progetti di ricerca finanziati dall’Università’ degli Studi di Torino and Regione Piemonte, Ricerca Scientifica Applicata project
- TAKTIC consortium
This publication has 47 references indexed in Scilit:
- The function of p27KIP1during tumor developmentExperimental & Molecular Medicine, 2009
- The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapyNature Reviews Cancer, 2008
- Differential Modification of p27 Kip1 Controls Its Cyclin D-cdk4 Inhibitory ActivityMolecular and Cellular Biology, 2008
- Cdk-Inhibitory Activity and Stability of p27 Are Directly Regulated by Oncogenic Tyrosine KinasesCell, 2007
- Regulation of the c-Abl and Bcr–Abl tyrosine kinasesNature Reviews Molecular Cell Biology, 2004
- Structural Basis for the Autoinhibition of c-Abl Tyrosine KinaseCell, 2003
- Deregulated degradation of the cdk inhibitor p27 and malignant transformationSeminars in Cancer Biology, 2003
- c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory TyrosinesJournal of Biological Chemistry, 2000
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complexNature, 1996